Mayo Clinic Arizona

Mayo Clinic Arizona, doing business as Mayo Foundation, is a nonprofit academic medical center and child entity of Mayo Clinic that delivers biomedical research services, clinical research support, and medical consulting to the federal government as a prime grant recipient across diverse federal agencies. Mayo Clinic Arizona competes in full-and-open federal grant environments without set-asides, acting as prime recipient on 70 percent of recent awards (225 of 321 total awards) and as a sub-recipient on 30 percent.

Mayo Clinic Arizona's federal footprint is heavily concentrated in NIH-sponsored biomedical research across cancer, cardiovascular disease, immunology, and neurodegenerative disease. The organization functions as prime recipient for project grants—the standard NIH assistance type—across the National Institutes of Health portfolio. Representative recent prime work includes a $319,195 National Cancer Institute project grant awarded September 1, 2026, to conduct a pilot feasibility trial of STRUM (Strengthening Teen Brain Resilience Using Music), a 10-week virtual music therapy intervention for adolescents undergoing radiation therapy for cancer, extending through August 31, 2029. Mayo Clinic Arizona also received a $1.665 million National Heart, Lung, and Blood Institute project grant on July 15, 2026, to investigate how P2RX7-expressing CD4+ T cells control virus-induced lung sequelae including long COVID and long flu, running through June 30, 2028. A $252,134 National Cancer Institute purchase order dated November 1, 2024, funds medical record abstraction services for the Pediatric Proton and Photon Therapy Comparison Cohort study through June 30, 2026. The Indian Health Service awarded an $638,583 purchase order on August 1, 2022, for hematology and oncology services and consulting at Phoenix Indian Medical Center, with performance extending through August 1, 2027.

Customer concentration is highly skewed toward NIH. The National Cancer Institute anchors 59 awards (accounting for 62 percent of all awards across the top five funding agencies), the National Heart, Lung, and Blood Institute holds 41 awards, and the National Institute of Allergy and Infectious Diseases holds 38 awards. Outside NIH, the Indian Health Service carries 14 awards with $1.6 million in combined potential value, representing the largest single dollar concentration. Over the past five years, award volume has grown from 15 awards in 2022 to 44 in 2024, with 27 awards placed through September 2026. Forty-five awards (combined potential value $639,000) reach completion within the next twenty-four months.

Mayo Clinic Arizona holds an Other Transaction IDV with the Defense Advanced Research Projects Agency (DARPA) for the Network of Optimal Dynamic Energy Signatures (NODES) program, with a ceiling of $1,288,748 awarded March 19, 2026. The organization also participates as a subcontractor on federal contracts and grants. Recent subcontract work includes statistical and analytic support to the Organ Procurement and Transplantation Network under a December 11, 2025, sub-award from Hennepin Healthcare Research Institute for continuation of the Scientific Registry of Transplant Recipients (SRTR). Mayo Clinic Arizona also serves as a clinical research site under multiple NIH-funded consortia, including sub-awards from Stanford University for the ARREST PNEUMONIA multicenter randomized controlled trial (December 5, 2023) and from Arizona State University for developmental programming and stem cell research (dated April 2026 and December 2025).

Mayo Clinic Arizona's grant portfolio spans immunology, oncology, pulmonary and cardiac regeneration, infectious disease, neurodegenerative disease, and health services research. The organization received $807,446 from the National Institute of Diabetes and Digestive and Kidney Diseases on February 1, 2026, to investigate the epigenetic basis of glucocorticoid action on pancreatic beta cells. A $1 million Defense Health Agency project grant transferred to Mayo Clinic Arizona on July 1, 2026, supports research on immune biomarkers in TDP-43 ALS patients and development of therapeutics for chemotherapy-induced peripheral neuropathy. The organization has also received Defense Health Agency funding for Phase 1 clinical trials ($3.291 million, September 2024) using autologous MUC1-activated T cells in ovarian cancer and for metabolic reprogramming of CAR macrophages ($408,467, September 2023).

As a nonprofit academic medical center, Mayo Clinic Arizona does not participate in SBA small-business set-asides. The organization competes and wins on the basis of scientific merit and clinical expertise in peer-reviewed federal grant mechanisms. Corporate structure identifies Mayo Clinic Arizona as a child entity of Mayo Clinic, a parent nonprofit organization headquartered in Rochester, Minnesota, with major operating campuses in Rochester, Jacksonville, and Phoenix/Scottsdale. Recent award activity indicates Mayo Clinic Arizona maintains active clinical research operations at its Scottsdale, Arizona location (13400 E Shea Boulevard), with performance also reported at a Phoenix facility.